Nurix Therapeutics (NRIX) Expected to Announce Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 10th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $16.26 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The company had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period in the previous year, the firm posted ($0.76) earnings per share. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Trading Up 2.3%

NASDAQ NRIX traded up $0.29 during trading hours on Friday, hitting $12.73. The company's stock had a trading volume of 279,635 shares, compared to its average volume of 836,838. The company has a market capitalization of $970.48 million, a PE ratio of -4.55 and a beta of 2.15. Nurix Therapeutics has a 52 week low of $8.18 and a 52 week high of $29.56. The company's 50-day simple moving average is $11.12 and its two-hundred day simple moving average is $14.06.

Analysts Set New Price Targets

NRIX has been the topic of several analyst reports. Wall Street Zen raised Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. Finally, Stifel Nicolaus reduced their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Nurix Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $30.18.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer owned 33,724 shares of the company's stock, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider directly owned 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,013 shares of company stock worth $137,096 in the last ninety days. Insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its holdings in Nurix Therapeutics by 106.2% during the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company's stock valued at $10,388,000 after acquiring an additional 450,262 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company's stock valued at $6,029,000 after purchasing an additional 44,002 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Nurix Therapeutics by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company's stock valued at $1,895,000 after purchasing an additional 12,817 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Nurix Therapeutics by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company's stock valued at $593,000 after purchasing an additional 5,286 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.